논문업데이트

Home. 최근뉴스. 논문업데이트

논문업데이트

Defining pollen exposure times for clinical trials of allergen immunot…

페이지 정보

작성자 관리자
댓글 0건 조회 1,261회 작성일 17-04-13 03:04

본문

Defining pollen exposure times for clinical trials of allergen immunotherapy for pollen-induced rhinoconjunctivitis
 
Allergy Volume 72, Issue 5,May 2017 Pages 713–722
 
O. Pfaar,K. Bastl,U. Berger,J. Buters,M. A. Calderon,B. Clot,U. Darsow,P. Demoly,S. R. Durham,C. Galán,R. Gehrig,R. Gerth van Wijk,L. Jacobsen,L. Klimek,M. Sofiev,M. Thibaudon,K. C. Bergmann
Abstract
Background
Clinical efficacy of pollen allergen immunotherapy (AIT) has been broadly documented in randomized controlled trials. The underlying clinical endpoints are analysed in seasonal time periods predefined based on the background pollen concentration. However, any validated or generally accepted definition from academia or regulatory authorities for this relevant pollen exposure intensity or period of time (season) is currently not available. Therefore, this Task Force initiative of the European Academy of Allergy and Clinical Immunology (EAACI) aimed to propose definitions based on expert consensus.
 
Methods
A Task Force of the Immunotherapy and Aerobiology and Pollution Interest Groups of the EAACI reviewed the literature on pollen exposure in the context of defining relevant time intervals for evaluation of efficacy in AIT trials. Underlying principles in measuring pollen exposure and associated methodological problems and limitations were considered to achieve a consensus.
 
Results
The Task Force achieved a comprehensive position in defining pollen exposure times for different pollen types. Definitions are presented for ‘pollen season’, ‘high pollen season’ (or ‘peak pollen period’) and ‘high pollen days’.
 
Conclusion
This EAACI position paper provides definitions of pollen exposures for different pollen types for use in AIT trials. Their validity as standards remains to be tested in future studies
  • 목록

    • 댓글목록

    등록된 댓글이 없습니다.